Enabling Large-Scale Pharmacogenetic Studies by High-Throughput Mutation Detection and Genotyping Technologies
Open Access
- 1 February 2001
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 47 (2) , 164-172
- https://doi.org/10.1093/clinchem/47.2.164
Abstract
Background: Pharmacogenetics is a scientific discipline that examines the genetic basis for individual variations in response to therapeutics. Pharmacogenetics promises to develop individualized medicines tailored to patients’ genotypes. However, identifying and genotyping a vast number of genetic polymorphisms in large populations also pose a great challenge. Approach: This article reviews the recent technology development in mutation detection and genotyping with a focus on genotyping of single nucleotide polymorphisms (SNPs). Content: Novel mutations/polymorphisms are commonly identified by conformation-based mutation screening and direct high-throughput heterozygote sequencing. With a large amount of public sequence information available, in silico SNP mapping has also emerged as a cost-efficient way for new polymorphism identification. Gel electrophoresis-based genotyping methods for known polymorphisms include PCR coupled with restriction fragment length polymorphism analysis, multiplex PCR, oligonucleotide ligation assay, and minisequencing. Fluorescent dye-based genotyping technologies are emerging as high-throughput genotyping platforms, including oligonucleotide ligation assay, pyrosequencing, single-base extension with fluorescence detection, homogeneous solution hybridization such as TaqMan®, and molecular beacon genotyping. Rolling circle amplification and InvaderTM assays are able to genotype directly from genomic DNA without PCR amplification. DNA chip-based microarray and mass spectrometry genotyping technologies are the latest development in the genotyping arena. Summary: Large-scale genotyping is crucial to the identification of the genetic make-ups that underlie the onset of diseases and individual variations in drug responses. Enabling technologies to identify genetic polymorphisms rapidly, accurately, and cost effectively will dramatically impact future drug and development processes.Keywords
This publication has 31 references indexed in Scilit:
- Technologies for detecting genetic polymorphisms in pharmacogenomicsMolecular Diagnosis, 1999
- High density synthetic oligonucleotide arraysNature Genetics, 1999
- Genetic Variation as a Guide to Drug DevelopmentScience, 1998
- Large-Scale Identification, Mapping, and Genotyping of Single-Nucleotide Polymorphisms in the Human GenomeScience, 1998
- Multicolor molecular beacons for allele discriminationNature Biotechnology, 1998
- Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization.Genome Research, 1995
- Detection of mutations by cleavage of DNA heteroduplexes with bacteriophage resolvasesNature Genetics, 1995
- Detection of mismatched bases in double stranded DNA by gel electrophoresisElectrophoresis, 1995
- F-SSCP: fluorescence-based polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) analysis.Genome Research, 1992
- Dideoxy fingerprinting (ddF): A rapid and efficient screen for the presence of mutationsGenomics, 1992